Objective Antibiotics are routinely used in the treatment of lung microbial infections and there is concern about the increasing number of lung pathogens which show antibiotic-resistance. Lung surfactant proteins A and D (SP-A and SP-D) are part of the naturally occurring innate immune system which provides an immediate defence against a wide range of lung pathogens (viruses, bacteria and fungi) and also have an anti-inflammatory forms of allergic reactions. Levels of SP-A -and SP-D fall during certain infections. thus the use of recombinant forms of these proteins may alleviate the need for administration of antibiotics, especially in the very young, ventilated patients and immunocompromised adults (such as AIDS patients). Recombinant forms of SP-A and SP-D will be directly tested as therapeutic agents and also after their addition to lung surfactant preparations which are in clinical use/or trials (which at present lack SP-A and SP-D). The recombinant forms of SP-A and SP-D will be fully characterised and their biological properties assessed by in vitro assays and in animal models of lung infection and inflammation. This will allow the formulation of the optimal recombinant forms of SP-A and SP-D for use in human clinical trials. Fields of science natural sciencesbiological sciencesbiochemistrybiomoleculesproteinsmedical and health sciencesbasic medicineimmunologymedical and health scienceshealth sciencesinfectious diseasesRNA virusesHIVmedical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsantibioticsmedical and health sciencesbasic medicinepharmacology and pharmacydrug resistanceantibiotic resistance Programme(s) FP5-LIFE QUALITY - Specific Programme for research, technological development and demonstration on "Quality of life and management of living resources", 1998-2002 Topic(s) 1.1.1.-2. - Key action Control of Infectious Diseases Call for proposal Data not available Funding Scheme CSC - Cost-sharing contracts Coordinator Medical Research Council (MRC) EU contribution No data Address 20 Park Crescent W1N 4AL London United Kingdom See on map Total cost No data Participants (4) Sort alphabetically Sort by EU Contribution Expand all Collapse all ALTANA PHARMA A.G. Germany EU contribution No data Address Byk-Gulden Str. 2 78467 KONSTANZ See on map Total cost No data UNIVERSIDAD COMPLUTENSE DE MADRID Spain EU contribution No data Address Ciudad Universitaria s/n 28040 MADRID See on map Total cost No data UNIVERSITY OF SOUTHERN DENMARK - UNIVERSITY OF ODENSE Denmark EU contribution No data Address Winsloeevparken 21 5000 ODENSE See on map Total cost No data UTRECHT UNIVERSITY Netherlands EU contribution No data Address Yalelaan 1 3584 CL UTRECHT See on map Total cost No data